Vietnamese pharmaceutical stocks turn out to be not hot or active on the stock market though they have posted solid earning results, stock analysts said.
Cuu Long Pharmaceutical JS Company (DCL) estimates to make a net profit of VND70 billion on revenues of VND550 billion and a dividend payment equivalent to VND2,500 this year, said Luong Van Hoa, chairman of the company.
DCL invested VND234 billion to build a factory to produce Capsul II and a new anti-body Cephalosporin producing factory in 2009 and will steadily invest in new projects to increase its competitiveness in the market, said Hoa.
HaTay Pharmaceutical Joint Stock Company (DHT) expects a net profit of VND15 billion on revenues of VND550 billion, and plans to pay a dividend payment equivalent to VND2,000 this year, said Le Van Lo, chair man of DHT.
DHT will invest VND10 billion to modernize its production assembly and focus on traditional medicines with profit targeted to rise 5% in 2010.
Traphaco Joint Stock Company (TRA) estimates a net profit of VND50 billion this year, up 20% from 2008, said Nguyen Huy Van, deputy general director of the company.
Van said TRA developed 5 new products in 2009 and put into operation the third branch in Nam Dinh province.
OPC Pharmaceutical JSC (OPC expects a net profit of VND65 billion on revenues VND360 billion this year, up 60% and 56% respectively from a year earlier, and plans to pay cash dividend of VND2000, said Le Nam, the company’s spokeswoman.
OPC made a pretax profit of VND65 billion on revenues of VND334 billion in the first 11 months of this year, she said.
The company will operate its new drug producing factory in Binh Duong province with an investment of VND160 billion, Nam said. (Investment Securities)
Vietnamese
